Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4).
Occupational exposure to acrylamide was associated with excess mortality from pancreatic cancer, though in the absence of dose-risk relationship. Few epidemiological studies have examined the association between acrylamide from diet and pancreatic cancer risk.



We considered this issue in a combined set of 1975 cases of pancreatic cancer and 4239 controls enrolled in six studies of the Pancreatic Cancer Case-Control Consortium (PanC4). We calculated pooled odds ratios (ORs) and their 95% confidence intervals (CI) by estimating study-specific ORs through multivariate unconditional logistic regression models and pooling the obtained estimates using random-effects models.



Compared with the lowest level of estimated dietary acrylamide intake, the pooled ORs were 0.97 (95% CI, 0.79-1.19) for the second, 0.91 (95% CI, 0.71-1.16) for the third, and 0.92 (95% CI, 0.66-1.28) for the fourth (highest) quartile of intake. For an increase of 10 µg/day of acrylamide intake, the pooled OR was 0.96 (95% CI, 0.87-1.06), with heterogeneity between estimates (I2 = 67%). Results were similar across various subgroups, and were confirmed when using a one-stage modelling approach.



This PanC4 pooled-analysis found no association between dietary acrylamide and pancreatic cancer.
Department of Clinical Sciences and Community Health, University of Milan, Milan.
C
C
Pelucchi
Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
V
V
Rosato
Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco.
P M
PM
Bracci
Department of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA.
D
D
Li
Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
R E
RE
Neale
Department of Neurosciences, Psychology, Drug Research and Children's Health, University of Florence, Florence.
E
E
Lucenteforte
Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN), Italy.
D
D
Serraino
School of Public Health, University of Minnesota, Minneapolis.
K E
KE
Anderson
Department of Epidemiology, Louisiana State University Health Sciences Center School of Public Health, New Orleans, USA.
E
E
Fontham
Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco.
E A
EA
Holly
Department of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, USA.
M M
MM
Hassan
Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, Aviano (PN), Italy.
J
J
Polesel
Department of Epidemiology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
C
C
Bosetti
School of Public Health, University of Minnesota, Minneapolis.
L
L
Strayer
Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock.
J
J
Su
The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, USA.
P
P
Boffetta
Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
E J
EJ
Duell
Department of Clinical Sciences and Community Health, University of Milan, Milan.
C
C
La Vecchia
D020106:Acrylamide / Q000009:adverse effects*; D016022:Case-Control Studies; D004032:Diet / Q000009:adverse effects*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000209:etiology*; D012307:Risk Factors
D020106:Acrylamide
acrylamide; case–control studies; pancreatic neoplasms; pooled-analysis; risk factors